MARKET

PULM

PULM

Pulmatrix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.260
-0.050
-3.82%
After Hours: 1.260 0 0.00% 19:54 03/05 EST
OPEN
1.270
PREV CLOSE
1.310
HIGH
1.310
LOW
1.120
VOLUME
3.59M
TURNOVER
--
52 WEEK HIGH
3.040
52 WEEK LOW
0.9000
MARKET CAP
70.69M
P/E (TTM)
-1.6016
1D
5D
1M
3M
1Y
5Y
GSX Techedu, Norwegian Cruise Line Holdings leads the premarket losers' pack
Evofem Biosciences EVFM -25% on Q4 earnings release.Super League Gaming (SLGG) -19%.GSX Techedu GSX -15% on Q4 earnings release.T2 Biosystems TTOO -10% on Q4 earnings release.Senseonics Holdings SENS -9% on Q4 earnings release.Aerpio Pharmaceuticals ARPO -...
Seekingalpha · 2d ago
8-K: Pulmatrix, Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 2d ago
BRIEF-Pulmatrix Provides A Pipeline And Business Update
reuters.com · 3d ago
Pulmatrix Provides a Pipeline and Business Update
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today provides an update on its business and p...
PR Newswire · 3d ago
Respiratory Devices Market Insights 2021 With Regional Overview, Investment Opportunities, Share, Gross Margin, Top Key Players, Supply Demand Scenario, Pricing Analysis and Forecast to 2026
The Express Wire · 02/19 10:19
8-K: Pulmatrix, Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/16 22:44
Pulmatrix closes $40M capital raise
Pulmatrix ([[PULM]] +5.4%) announces that it has closed its previously announced registered direct offering with certain healthcare-focused institutional investors for the sale of 20M shares with gross proceeds of $40M.The
Seekingalpha · 02/16 18:35
Pulmatrix Announces Closing of $40 Million Registered Direct Offering
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced that it has closed its previou...
PR Newswire · 02/16 18:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PULM. Analyze the recent business situations of Pulmatrix through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PULM stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 41
Institutional Holdings: 8.15M
% Owned: 14.52%
Shares Outstanding: 56.11M
TypeInstitutionsShares
Increased
7
877.28K
New
7
10.62K
Decreased
8
171.84K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Independent Director
Michael Higgins
Chief Executive Officer/Director
Ted Raad
President/Chief Executive Officer/Director
Teofilo Raad
Vice President - Finance
Michelle Siegert
Director
Todd Bazemore
Director
Christopher Cabell
Independent Director
Rick Batycky
Independent Director
Mark Iwicki
Independent Director
Amit Munshi
No Data
  • All
  • Financials
  • Insiders
More
About PULM
Pulmatrix, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing inhaled therapies to address serious respiratory disease. The Company designs and develops inhaled therapeutic products based on its dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways. iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with a broad range of drug substances including small molecules and biologics. The Company’s therapeutic candidates are Pulmazole, PUR1800, PUR5700, PUR3000 and PUR4000.

Webull offers kinds of Pulmatrix Inc stock information, including NASDAQ:PULM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PULM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PULM stock methods without spending real money on the virtual paper trading platform.